Our website uses its own and third parties cookies for a high level of user-friendliness. If you continue to browse and  use this website we will assume that you agree with the policies.


Atrys Health liquid biopsy R&D project with HM

January 31, 2017

Madrid, January 31, 2017.- HM Hospitals, through the HM Hospitales Research Foundation, and Atrys Health, a company specialized in diagnostic services and advanced oncology treatments, have reached an agreement for the industrial development of the first marker of brain tumor in Glibioliquid, a diagnostic kit from a liquid biopsy for the dynamic evaluation of a significant number of predictive biomarkers using a simple blood test.